Shares of GlycoMimetics Inc (NASDAQ:GLYC) have received a consensus recommendation of “Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $21.00.

Several equities research analysts recently weighed in on GLYC shares. Zacks Investment Research upgraded shares of GlycoMimetics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Monday, November 13th. Roth Capital started coverage on shares of GlycoMimetics in a research report on Monday, October 23rd. They issued a “buy” rating and a $25.00 price target on the stock. Cowen restated a “buy” rating on shares of GlycoMimetics in a research report on Wednesday, December 6th. SunTrust Banks boosted their price target on shares of GlycoMimetics to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Finally, Jefferies Group reiterated a “buy” rating and set a $16.00 price objective on shares of GlycoMimetics in a research report on Thursday, October 26th.

Shares of GlycoMimetics (NASDAQ GLYC) traded up $0.29 on Tuesday, reaching $17.08. 502,258 shares of the company traded hands, compared to its average volume of 504,900. GlycoMimetics has a 12 month low of $3.82 and a 12 month high of $18.25. The company has a market capitalization of $584.43, a PE ratio of -13.77 and a beta of 3.21.

GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. sell-side analysts expect that GlycoMimetics will post -1.12 EPS for the current year.

In other news, SVP Helen M. Thackray sold 2,000 shares of the business’s stock in a transaction on Friday, December 8th. The shares were sold at an average price of $15.01, for a total transaction of $30,020.00. Following the completion of the sale, the senior vice president now directly owns 148,615 shares of the company’s stock, valued at $2,230,711.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 43.80% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Fox Run Management L.L.C. purchased a new stake in shares of GlycoMimetics during the third quarter valued at about $173,000. Dynamic Technology Lab Private Ltd acquired a new position in GlycoMimetics in the 2nd quarter worth approximately $146,000. Citadel Advisors LLC acquired a new position in GlycoMimetics in the 2nd quarter worth approximately $249,000. Russell Investments Group Ltd. grew its stake in shares of GlycoMimetics by 172.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 31,379 shares of the biotechnology company’s stock worth $350,000 after purchasing an additional 19,859 shares during the period. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of GlycoMimetics during the 2nd quarter worth approximately $569,000. 86.66% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “GlycoMimetics Inc (GLYC) Given Average Rating of “Buy” by Analysts” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/01/02/glycomimetics-inc-glyc-given-average-rating-of-buy-by-analysts.html.

About GlycoMimetics

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Analyst Recommendations for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.